The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | AML in 2022 and beyond
In this video, Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses ongoing research in acute myeloid leukemia (AML) and novel agents under investigation. Following this, Dr Fathi comments on how the combination of azacitidine and venetoclax have transformed the AML treatment landscape, and further highlights an ongoing Phase II study comparing this combination versus conventional chemotherapy in induction-eligible patients (NCT04801797). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Clinical trial support – Abbvie, Servier, BMS
Consulting – Abbvie, Servier, BMS, Genentech, PureTech, Ipsen, Forma, Kite, Celgene, Amgen, Novartis, Takeda, Astellas, Immunogen, Mablytics, EnClear, Orum
